In 2010, our practice will continue to conduct investigational studies in hepatitis C, making of use of new, very effective drugs to combat chronic hepatitis C. For most of the studies, they will include genotype 1 patients, who have never received any form of antiviral therapy against their hepatitis C. These naive patients will receive a three or four drug combination, with expected response rates of over 90%. Additionally, studies with patients previously treated will also become availabe later in 2010.
If interested, contact Herman Ortiz, Research Specialists of Texas, at 713-794-0700.
Update: We are actively enrolling patients for several hepatitis C studies. As noted above, this will be naive genotype 1 individuals, as well as those previously treated with any of the PEG-Interferon and ribavirin combinations. This would include therapy with PEG-Intron and well as Pegasys.
Enrollment is starting now. Contact Herman Ortiz at Research Specialists of Texas at 713-794-0700.
www.texasliver.com
Posted by: Joseph S. Galati, M.D. | February 28, 2010 at 04:41 PM